Omeicos Therapeutics, a biopharmaceutical spinout of research institute Max Delbrück Center for Molecular Medicine, achieved a first close of its series B round at €8.3m ($8.7m) on Wednesday.
The round was co-led by Vesalius Biocapital and plant construction company SMS Group.
German state-owned development bank KFW and public-private partnership High-Tech Gründerfonds (HTGF) and Ascension, a tech transfer office for a range of German universities, hospitals and institutes, also participated, as did VC Fonds Technologie Berlin, Falck Revocable Trust…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?